HDT Bio Announces Completion of Seed Financing Round
10/05/20, 1:04 PM
Location
seattleRound Type
seed
HDT Bio Corp., a biotechnology company enabling global access to immunotherapies for oncology and infectious disease, has announced the close of its seed financing round totaling ~$3 million. The round was co-led by Zoic Capital and joined by angel investors from multiple biotechnology hubs. Proceeds will be used largely to support continued development of the company’s COVID-19 vaccine candidate, HDT-301. The vaccine is slated to enter clinical trials in Q4 2020 in partnership with the NIH/NIAID.
Company Info
Location
seattle, washington, united states
Additional Info
ABOUT HDT BIO CORP: HDT Bio Corp’s mission is to bring immunotherapies to people around the world. With a focus on RNA, formulation, and adjuvant technologies, HDT Bio is developing biotherapeutics for oncology and infectious disease applications. HDT Bio simultaneously works to integrate therapeutic approaches for first-in-class medicines while building on decades of development experience with well-established pharmaceutical ingredients. The resulting products are poised to significantly improve the lives of millions of people worldwide and to provide access to lifesaving therapies for underserved populations. One of the company’s core technologies, RNA/LION™, combines formulation and adjuvant ingredients to stabilize and deliver RNA to the immune system to stimulate responses for therapy or vaccination. http://hdt.bio